Completed PHASE3 INTERVENTIONAL 7-arm NCT00861380

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)

Sponsor: GlaxoSmithKline

Conditions Infections, Streptococcal Streptococcus Pneumoniae

Interventions GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine) GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine) Pneumococcal conjugate vaccine GSK1024850A

Updated 7 times since 2017 Last updated: Nov 20, 2020 Started: May 4, 2009 Primary completion: Jan 31, 2012 Completion: Oct 5, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00861380, this PHASE3 trial focuses on Infections, Streptococcal and Streptococcus Pneumoniae and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Oct 2020 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland